BIOA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Bioage Labs's net margin of 10.05%. Bioage Labs's return on equity of -- beat Electromed's return on equity of 15.62%.

Bioage Labs has a consensus price target of $6.33, signalling upside risk potential of 23.22%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could fall by -2.94%. Given that Bioage Labs has higher upside potential than Electromed, analysts believe Bioage Labs is more attractive than Electromed.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Bioage Labs's net income of -$13.6M is lower than Electromed's net income of $1.5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Electromed's PE ratio is 47.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 5.31x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Bioage Labs's net margin of 8.48%. Bioage Labs's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Bioage Labs has a consensus price target of $6.33, signalling upside risk potential of 23.22%. On the other hand Eli Lilly and has an analysts' consensus of $977.47 which suggests that it could grow by 34.69%. Given that Eli Lilly and has higher upside potential than Bioage Labs, analysts believe Eli Lilly and is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.30 per share. Bioage Labs pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bioage Labs quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Bioage Labs's net income of -$13.6M is lower than Eli Lilly and's net income of $970.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 78.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 16.06x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Bioage Labs's net margin of 36.03%. Bioage Labs's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Bioage Labs has a consensus price target of $6.33, signalling upside risk potential of 23.22%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,005.61 which suggests that it could grow by 47.54%. Given that Regeneron Pharmaceuticals has higher upside potential than Bioage Labs, analysts believe Regeneron Pharmaceuticals is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Bioage Labs's net income of -$13.6M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Bioage Labs's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 5.67x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Bioage Labs's net margin of -63.65%. Bioage Labs's return on equity of -- beat Revance Therapeutics's return on equity of --.

Bioage Labs has a consensus price target of $6.33, signalling upside risk potential of 23.22%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 107.53%. Given that Revance Therapeutics has higher upside potential than Bioage Labs, analysts believe Revance Therapeutics is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.274%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Bioage Labs's net income of -$13.6M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Bioage Labs's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 1.39x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.